Weekly Epoetin Beta Maintains Haemoglobin Levels and Improves Quality of Life in Patients with Non-Myeloid Malignancies Receiving Chemotherapy

Suzuki, Yasuhiro; Tokuda, Yutaka; Fujiwara, Yasuhiro; Minami, Hironobu; Ohashi, Yasuo; Saijo, Nagahiro

doi:10.1093/jjco/hyn002

Cited by 11 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the low incidence of TEE and the lack of a structured approach for identifying TEE we could not conduct a detailed analysis, but in general the incidence of TEE in Japanese patients is considered to be low . Previous studies of ESA (not included in the present study) showed that few Japanese CIA patients treated with ESA or placebo experienced TEE …”

Section: Discussionmentioning

confidence: 88%

Meta‐analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy‐induced anemia and mortality: Individual patient data from Japanese randomized, placebo‐controlled trials

et al. 2013

View full text Add to dashboard Cite

Erythropoiesis-stimulating agents (ESA) reduce the need for transfusions and improve the quality of life in patients receiving chemotherapy, but several clinical trials have suggested that ESA might have a negative impact on survival. To evaluate the efficacy and safety of ESA, epoetin beta and darbepoetin alfa, including their impact on overall survival and thromboembolic events, we conducted an individual data-based meta-analysis of three randomized, placebo-controlled trials studying Japanese patients with chemotherapy-induced anemia. All trials were conducted in compliance with Good Clinical Practice. A total of 511 patients with solid tumor or lymphoma (epoetin beta or darbepoetin alfa, n = 273; placebo, n = 238) were included. The ESA significantly reduced the risk of transfusion (relative risk, 0.47; 95% confidence interval, 0.29-0.76). No significant effect of the ESA on overall survival was observed (unadjusted hazard ratio, 1.00; 95% confidence interval, 0.75-1.34). A prespecified subgroup analysis showed no strong interaction between the baseline hemoglobin concentration and the effect of ESA on overall survival. Among the ESA-treated patients, the highest hemoglobin achieved during the treatment period in each patient had no impact on mortality. No increase in thromboembolic events was observed in the ESA-treated patients (0.7% vs 1.7% placebo). The ESA reduced the risk of transfusion without a negative impact on the survival of patients with chemotherapy-induced anemia. (Cancer Sci 2013; 104: 481-485)

show abstract

Section: Discussionmentioning

confidence: 88%

Meta‐analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy‐induced anemia and mortality: Individual patient data from Japanese randomized, placebo‐controlled trials

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Anaemia, a common occurrence in cancer patients, not only has a profound impact on their quality of life (QoL) and functional status, but is also associated with poor treatment outcome and overall survival [1][2][3][4][5][6]. In fact, many of the complications of cancer and subsequent anticancer therapies are clinically damaging as a result of adverse effects on normal haematopoietic mechanisms.…”

Section: Introductionmentioning

confidence: 99%

“…Recombinant human erythropoetins (epoetins), including epoetin-beta (EB), have a proven effi cacy and safety record across many malignancy types, reducing the need for transfusion and improving QoL [3,[12][13][14][15][16][17][18]. Despite recent concerns, new studies have demonstrated that administration of epoetin in accordance with the 2007 updated guidelines [19] translates into improvements in Hb outcomes [20,21].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of epoetin-beta 30,000 IU/week in correcting anaemia in patients with gastrointestinal tumours subjected to concomitant chemoradiotherapy

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Several reports have confirmed that epoetin-beta (EB), a recombinant human erythropoietin, is effective increasing Hb levels, reducing transfusion requirements and improving QoL of patients with cancer-related anemia [15][16][17][18]. Despite recent concerns regarding the safety of erythropoietin stimulating agents, new studies have demonstrated that administration of epoetin in accordance with the 2007 updated guidelines [19] translates in improvements in Hb outcomes [20,21].…”

Section: Introductionmentioning

confidence: 99%

Anemia response and safety to epoetin-beta treatment in patients with neoadjuvant therapy prior to primary digestive tract tumor surgery

Gómez

Salgado

Valladares‐Ayerbes

et al. 2009

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

Purpose Anemia is common during anticancer treatment. This study aimed to evaluate the response and safety of treatment with epoetin-beta (EB) in patients with neoadjuvant therapy prior to primary digestive tract tumor surgery. Patients and methodsIn this open-label, single-arm study, patients (n = 22) with hemoglobin (Hb) levels below 11 g/dl who received epoetin-beta 450 IU/kg (30,000 IU) weekly until the hemoglobin level reached 12 g/dl.Results After treatment with EB, a mean absolute increment of 2.6 g/dl was attained. The mean hemoglobin values during the study were pretreatment 10.1 g/dl, half-way through treatment 12.3 g/dl, 4 weeks after concomitant radiochemotherapy 12.7 g/dl, the week prior to surgery 12.5 g/dl, and after surgery 10.9 g/dl. No patient required transfusion before or after surgery. The probability or risk of postoperative complications was 27.3%, and included one rectovaginal fistula, one parastomal hernia, one case of ileus and two surgical wound infections. In this series, downstaging was observed in 81.8% of patients, and downsizing in 90.9%. Most interestingly, histopathological complete response rate was achieved by 18.2%. Conclusions Epoetin-beta (EB) treatment in our series of patients with digestive malignancies subjected to neoadjuvant radiochemotherapy proved effective and safe, avoiding the need for transfusion during surgery.

show abstract

Weekly Epoetin Beta Maintains Haemoglobin Levels and Improves Quality of Life in Patients with Non-Myeloid Malignancies Receiving Chemotherapy

Abstract: Epoetin beta administered at an initial dose of 36 000 IU once-weekly was well tolerated, with increased haemoglobin levels and improved QOL in anaemic cancer patients receiving myelosuppressive chemotherapy.

Cited by 11 publications

References 19 publications

Meta‐analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy‐induced anemia and mortality: Individual patient data from Japanese randomized, placebo‐controlled trials

Meta‐analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy‐induced anemia and mortality: Individual patient data from Japanese randomized, placebo‐controlled trials

Efficacy of epoetin-beta 30,000 IU/week in correcting anaemia in patients with gastrointestinal tumours subjected to concomitant chemoradiotherapy

Anemia response and safety to epoetin-beta treatment in patients with neoadjuvant therapy prior to primary digestive tract tumor surgery

Contact Info

Product

Resources

About